1. Home
  2. RIGL vs CASS Comparison

RIGL vs CASS Comparison

Compare RIGL & CASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • CASS
  • Stock Information
  • Founded
  • RIGL 1996
  • CASS 1906
  • Country
  • RIGL United States
  • CASS United States
  • Employees
  • RIGL N/A
  • CASS N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • CASS Business Services
  • Sector
  • RIGL Health Care
  • CASS Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • CASS Nasdaq
  • Market Cap
  • RIGL 537.6M
  • CASS 503.5M
  • IPO Year
  • RIGL 2000
  • CASS 1996
  • Fundamental
  • Price
  • RIGL $29.48
  • CASS $39.74
  • Analyst Decision
  • RIGL Buy
  • CASS Buy
  • Analyst Count
  • RIGL 5
  • CASS 2
  • Target Price
  • RIGL $38.20
  • CASS $45.50
  • AVG Volume (30 Days)
  • RIGL 492.6K
  • CASS 90.5K
  • Earning Date
  • RIGL 11-04-2025
  • CASS 10-23-2025
  • Dividend Yield
  • RIGL N/A
  • CASS 3.28%
  • EPS Growth
  • RIGL N/A
  • CASS 38.38
  • EPS
  • RIGL 5.43
  • CASS 2.31
  • Revenue
  • RIGL $267,921,000.00
  • CASS $222,318,000.00
  • Revenue This Year
  • RIGL $59.93
  • CASS N/A
  • Revenue Next Year
  • RIGL N/A
  • CASS $7.81
  • P/E Ratio
  • RIGL $5.44
  • CASS $19.62
  • Revenue Growth
  • RIGL 105.62
  • CASS 5.44
  • 52 Week Low
  • RIGL $13.57
  • CASS $36.08
  • 52 Week High
  • RIGL $43.72
  • CASS $47.14
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 46.18
  • CASS 56.59
  • Support Level
  • RIGL $29.30
  • CASS $36.07
  • Resistance Level
  • RIGL $30.94
  • CASS $40.13
  • Average True Range (ATR)
  • RIGL 1.26
  • CASS 1.00
  • MACD
  • RIGL 0.38
  • CASS 0.41
  • Stochastic Oscillator
  • RIGL 53.61
  • CASS 90.38

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About CASS Cass Information Systems Inc

Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.

Share on Social Networks: